Aligning Capital with Compliance and IP Value – Duane Morris Life Sciences Law

By Driscoll R. Urgate, P.A.

Financing and exit transactions in the life sciences industry differ fundamentally from those in traditional technology or manufacturing sectors. Scientific risk, regulatory oversight, and intellectual property rights intersect at every stage of a company’s growth, from seed capital through commercialization and acquisition. Investors and acquirers do not simply value a company’s technology, they assess its regulatory posture, data integrity, and the duration and durability of its exclusivity.

This article explores how capital-raising and exit strategies in life sciences require a multidisciplinary approach that integrates corporate structure, intellectual property strategy, and FDA compliance. It provides information for executives and general counsel navigating venture financings, public offerings, and M&A exits, and offers practical steps for aligning legal and operational strategy to preserve and enhance enterprise value.

Read the full article on the Duane Morris website.